The two domains in analytic pharmacology ambidextrous with optimizing dosing recommendations are pharmacokinetics and pharmaco dynamics. However, the account of these disciplines is bound if beheld in isolation. Pharmacokinetic/pharma codynamic (PK/PD) relationships and modeling builds the arch amid these two classical disciplines of clinical pharmacology. It links the concentration-time profile as adjourned by pharmacokinetics to the acuteness of observed response as quantified by pharmaco dynamics. Thus, the resulting so called chip PK/PD-models acquiesce the description of the complete time advance of the adapted and/or undesired effects in acknowledgment to a biologic therapy. PK/PD-modeling can annotate the adroit accord amid biologic exposure and acknowledgment and accommodate a bigger compassionate of the sequence of contest that after effect in the empiric biologic effect. This advice can again be acclimated to accumulate the biologic development process and dosage optimization. The purpose of this review was to systemize recent approaches on accompaniment of PK/PD modeling from an academic, automated and regulatory perspective.The two domains in analytic pharmacology ambidextrous with optimizing dosing recommendations are pharmacokinetics and pharmaco dynamics. However, the account of these disciplines is bound if beheld in isolation. Pharmacokinetic/pharma codynamic (PK/PD) relationships and modeling builds the arch amid these two classical disciplines of clinical pharmacology. It links the concentration-time profile as adjourned by pharmacokinetics to the acuteness of observed response as quantified by pharmaco dynamics. Thus, the resulting so called chip PK/PD-models acquiesce the description of the complete time advance of the adapted and/or undesired effects in acknowledgment to a biologic therapy. PK/PD-modeling can annotate the adroit accord amid biologic exposure and acknowledgment and accommodate a bigger compassionate of the sequence of contest that after effect in the empiric biologic effect. This advice can again be acclimated to accumulate the biologic development process and dosage optimization. The purpose of this review was to systemize recent approaches on accompaniment of PK/PD modeling from an academic, automated and regulatory perspective